Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Combination trials featuring immune checkpoint inhibitors may not result in synergistic effects, says GlobalData

Increasingly, over the past decade pharmaceutical companies have sought to enhance the efficacy of Immune checkpoint inhibitors (ICIs) by using these in combination with other ICIs, chemotherapies, small molecules or cell therapies says GlobalData, the leading data and analytics company. ICIs are very widely used in oncology and include blockbuster drugs Merck & Co.’s Keytruda […]
Read more

Novel CAR-T cell approaches of Chinese pharma promote clinical innovation and can address remaining unmet needs, says GlobalData

Chinese pharma companies are continuously focusing on the research and development of new innovative oncology therapies. Recently, Innovent Biologics and Gracell Biotechnologies have initiated Phase I trials for their innovative chimeric-antigen receptor T (CAR-T) therapies. It could further address remaining unmet needs, says GlobalData, a leading data and analytics company. Gracell Biotechnologies’ GC012F is developed […]
Read more

AML treatment landscape in China evolving with availability of multiple precision therapy options, says GlobalData

China has recently approved CStone Pharmaceuticals’ Tibsovo (ivosidenib tablets) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, providing a new precision therapy for this patient population. With multiple precision therapies now available, the cancer treatment arsenal is expanding for adult acute myeloid leukemia […]
Read more

Early results highlight ZT-01’s ability to restore glucagon regulation in type 1 diabetics, says GlobalData

Zucara Therapeutics recently announced the publication of ZT-01 preclinical data for the treatment of insulin-induced hypoglycemia in patients with type 1 diabetes (T1D). Zucara is currently conducting a Phase 1b proof-of-concept clinical trial in people with T1D, with results anticipated in Q2 2022. With few therapeutics in development that focus on hypoglycemic prevention specifically, GlobalData […]
Read more

Ardelyx’s tenapanor has potential to capture a slice of the CKD-HP market, says GlobalData

Ardelyx’s tenapanor has the potential to capture a slice of the chronic kidney disease (CKD)-hyperphosphatemia (HP) market if the company can successfully appeal the Food and Drug Administration’s Appeal Denied Letter (ADL), says GlobalData. The leading data and analytics company notes that tenapanor’s potential is based on its ability to target dialysis-dependent patients who are […]
Read more

Novartis’ Leqvio has potential to lead the cholesterol-lowering space due to its administration convenience, says GlobalData

Sales for Novartis’ Leqvio (inclisiran) for the treatment of high cholesterol may surpass those of Sanofi/Regeneron’s Repatha (evolocumab) and Amgen’s Praluent (alirocumab) by 2027 due to its administration convenience, according to GlobalData. The leading data and analytics company notes that Leqvio is in a better position compared to its competitors as it is administered by […]
Read more
, ,

GlobalData partners with Snowflake to empower seamless access and delivery of its data

GlobalData’s Marketplace is now accessible via Snowflake’s cloud data platform, empowering seamless access and direct integration of GlobalData’s intelligence into customer applications and data operations.  London – February 21, 2022 – GlobalData Plc (LSE: DATA), a leading intelligence platform for the world’s largest industries, has announced a partnership with Snowflake, a premier data warehouse built […]
Read more

Promising pipeline drugs to transform the Fragile X Syndrome treatment market by 2030, says GlobalData

By 2030, GlobalData highlights that promising pipeline drugs Zygel, zatolmilast, trofinetide, and acamprosate calcium SR are set to offer new treatment options for people with Fragile X Syndrome (FXS)—a rare genetic disorder that is the leading cause of inherited intellectual disability. The leading data and analytics company notes that these products will help propel the […]
Read more

Haplo-cord treatment may provide permanent cure for over 37.7 million HIV sufferers, says GlobalData

Following the recent news that the woman referred to as ‘the New York patient’, who received haplo-cord treatment four years ago, is now off HIV medication and remains asymptomatic and healthy: Sultan Ahmed, Infectious Disease Analyst at GlobalData, a leading data and analytics company, offers his view: “The haplo-cord transplant, conventionally used for cancer treatment, […]
Read more

Global chronic myeloid leukemia market set to decline due to most medication losing patent protection by 2030, says GlobalData

The chronic myeloid leukemia (CML) therapy market is dominated by tyrosine kinase inhibitors (TKIs) targeting aberrant BCR-ABL1. However, with all but one of the currently marketed BCR-ABL1 TKIs due to lose patent protection by 2030, the global market is set to decline from $4.25 billion in 2020 to $3.35 billion in 2030, says GlobalData. According […]
Read more

Delay in launch of indigenous COVID-19 vaccines by Japanese pharma will impact domestic market potential, says GlobalData

Pharma companies in Japan are still working to bring their first COVID-19 indigenous vaccine, though the pandemic has already completed two years in various parts of the world. As a result, any further delay in the launch of indigenous COVID-19 vaccines will impact domestic market potential, says GlobalData, a leading data and analytics company. According […]
Read more

GlobalData sees significant gap in digital marketing for obesity in Australia

Obesity is a key public health concern and a leading risk factor for other lifestyle-related illnesses in Australia. Currently, four key pharma companies offer marketed therapies for the treatment of obesity. However, digital support is limited to just Novo Nordisk and iNova Pharmaceuticals. Against this backdrop, other key players in Australia’s obesity market have significant […]
Read more

AI together with Big Data will be the most disruptive emerging technology duo in the pharmaceutical sector in 2022, says GlobalData

Despite being years away from exhibiting its full potential, artificial intelligence (AI), together with Big Data, stand out as a versatile combination to address challenges faced by the entire pharmaceutical value chain, says GlobalData, a leading data and analytics company. In GlobalData’s latest report, ‘The State of the Biopharmaceutical Industry – 2022’, AI, followed by […]
Read more

Drug pricing and reimbursement-related concerns will remain the leading impediment to the pharmaceutical industry’s growth in 2022, says GlobalData

Drug pricing pressures will continue to hinder the growth of the pharmaceutical industry in 2022, forcing companies to reassess their pricing strategies and market focus, says GlobalData, a leading data and analytics company. In GlobalData’s latest report, ‘The State of the Biopharmaceutical Industry – 2022’, drug pricing and reimbursement constraints elicited the strongest responses from […]
Read more
1 … 51 52 53 54 55 … 110